Oisin Biotechnologies Revenue and Competitors

Seattle, WA USA

Location

$7.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Oisin Biotechnologies's estimated annual revenue is currently $1.6M per year.(i)
  • Oisin Biotechnologies's estimated revenue per employee is $77,500
  • Oisin Biotechnologies's total funding is $7.1M.

Employee Data

  • Oisin Biotechnologies has 20 Employees.(i)
  • Oisin Biotechnologies grew their employee count by -9% last year.

Oisin Biotechnologies's People

NameTitleEmail/Phone
1
Co-Founder and Scientific AdvisorReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Business OfficerReveal Email/Phone
4
Co-founder & Chief Science OfficerReveal Email/Phone
5
Lead ScientistReveal Email/Phone
6
Executive Chairman and Co-FounderReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Oisin Biotechnologies?

Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

keywords:N/A

$7.1M

Total Funding

20

Number of Employees

$1.6M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Oisin Biotechnologies News

2022-04-17 - Longevity and Anti-senescence Therapy Market to Reach ...

Merck & Co., Inc. Oisin Biotechnologies; Pfizer Inc. T.A. Sciences, Inc. Unity Biotechnology, Inc. Avenue Basic Plan | Library Access | 1 Year...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.8M20-23%N/A
#2
$1.4M2011%$18.5M
#3
$1.4M20-9%$12.5M
#4
$2M20N/AN/A
#5
$2M20N/AN/A